AMPH

#2482
Amphastar Pharmaceuticals, Inc.
21.7100 USD
+1.54%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
21.5100
21.7600
Годовой диапазон
17.0300
29.5200
Дневное изменение
+1.54%
Месячное изменение
+14.69%
6-месячное изменение
-10.95%
Годовое изменение
-10.95%
Предыдущее закрытие
21.3800
Открыть
21.5200
Bid
Ask
Минимум
21.5100
High
21.7600
Объем
228
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 984.9864 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
13.19
Коэффициент цена/денежный поток
1.79

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Новости